Edelstein Celina, Philips Binu, Pfaffinger Ditta, Scanu Angelo M
University of Chicago, Department of Medicine, 5841 S. Maryland Ave, Chicago, IL 60637, USA.
FASEB J. 2009 Mar;23(3):950-6. doi: 10.1096/fj.08-122002. Epub 2008 Nov 10.
Lipoprotein (a) [Lp(a)], a cardiovascular risk factor, is a low-density lipoprotein (LDL) variant shown to bind to oxidized phospholipids (oxPLs); however, its binding mode and origin have not been clearly established. We isolated both LDL and Lp(a) from the plasma of a population of high-Lp(a) subjects and in each Lp(a) particle separated apolipoprotein(a) [apo(a)], from the LDL component, Lp(a(-)). These products were assayed by an ELISA using monoclonal antibody T15 with a known specificity for oxPLs. In each subject, the T15 reactivity was confined to apo(a). Moreover, the amount of oxPL bound to apo(a) was unaffected by plasma Lp(a) levels and apo(a) size polymorphism. We have previously shown that kringle V (KV) is the site of oxPL linkage in human apo(a). In this work, we expressed in human embryonic kidney cells a KV-containing recombinant that, when purified from the medium, contained oxPLs. In summary, in human plasma Lp(a), the oxPLs are located in apo(a) and not in the circulating LDLs, suggesting a cellular origin. This latter concept is supported by the studies in which an expressed KV-containing apo(a) microdomain exhibited oxPL reactivity. Thus, apo(a) can undergo potentially pathogenic posttranslational modifications in a cellular environment able to generate oxPL.
脂蛋白(a)[Lp(a)]是一种心血管危险因素,是一种低密度脂蛋白(LDL)变体,已被证明可与氧化磷脂(oxPLs)结合;然而,其结合模式和来源尚未明确。我们从高Lp(a)受试者群体的血浆中分离出LDL和Lp(a),并在每个Lp(a)颗粒中从LDL成分Lp(a-)中分离出载脂蛋白(a)[apo(a)]。使用对oxPLs具有已知特异性的单克隆抗体T15通过ELISA对这些产物进行检测。在每个受试者中,T15反应性仅限于apo(a)。此外,与apo(a)结合的oxPL量不受血浆Lp(a)水平和apo(a)大小多态性的影响。我们之前已经表明,kringle V(KV)是人apo(a)中oxPL连接的位点。在这项工作中,我们在人胚肾细胞中表达了一种含KV的重组体,当从培养基中纯化时,其含有oxPLs。总之,在人血浆Lp(a)中,oxPLs位于apo(a)中而非循环LDL中,提示其细胞来源。这一概念得到了相关研究的支持,在这些研究中,一个表达的含KV的apo(a)微结构域表现出oxPL反应性。因此,apo(a)在能够产生oxPL的细胞环境中可能会经历潜在的致病性翻译后修饰。